Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma
Pranabashis Haldar Respiratory Biomedical Research Unit, Glenfield Hospital, University of Leicester, Leicester, UK Abstract: Mepolizumab (Nucala®) is an effective and specific anti-eosinophil molecular therapy that has recently been approved as add-on therapy for the management of severe eo...
Saved in:
Main Author: | Haldar P |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2017
|
Subjects: | |
Online Access: | https://doaj.org/article/111bf5d433994f3c93b4a3dfd6b4a85f |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Real-Life Effectiveness of Mepolizumab on Forced Expiratory Flow between 25% and 75% of Forced Vital Capacity in Patients with Severe Eosinophilic Asthma
by: Angelantonio Maglio, et al.
Published: (2021) -
Development of Rheumatoid Arthritis During Anti-Interleukin-5 Therapy in a Patient with Refractory Chronic Eosinophilic Pneumonia
by: Kawabata H, et al.
Published: (2021) -
New horizons for the treatment of severe, eosinophilic asthma: benralizumab, a novel precision biologic
by: Caminati M, et al.
Published: (2019) -
A patient case demonstrating the efficacy of benralizumab in uncontrolled severe eosinophilic asthma refractory to omalizumab and mepolizumab treatment
by: John Davison, et al.
Published: (2021) -
Stability of blood eosinophils in acute exacerbation of chronic obstructive pulmonary disease and its relationship to clinical outcomes: a prospective cohort study
by: Yanan Cui, et al.
Published: (2021)